Bristol-Myers Squibb: Pulmonary Embolism trials
The registry lists 10 Pulmonary Embolism studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 2 2Phase 3 7No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary EmbolismCompletedNCT00643201Phase 3Results posted
- Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary EmbolismCompletedNCT00633893Phase 3Results posted
- Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical IllnessCompletedNCT00457002Phase 3Results posted
- Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement SurgeryCompletedNCT00452530Phase 3Results posted
- Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)CompletedNCT00423319Phase 3Results posted
- Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement SurgeryCompletedNCT00371683Phase 3Results posted
- A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) CancerCompletedNCT00320255Phase 2Results posted
- The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the LungCompletedNCT03595891
- Early Post-Marketing Study of ELIQUIS (Apixaban) in MexicoCompletedNCT02345343
- BMS-562247 in Subjects Undergoing Elective Total Knee Replacement SurgeryCompletedNCT00097357Phase 2/3